Net margin is calculated as Net Income divided by its Revenue. PT Indofarma Tbk's Net Income for the
three
months ended in Dec. 2025 was Rp49,102 Mil. PT Indofarma Tbk's Revenue for the
three
months ended in Dec. 2025 was Rp17,815 Mil. Therefore, PT Indofarma Tbk's net margin for the quarter that ended in Dec. 2025 was 275.62%.
The historical rank and industry rank for PT Indofarma Tbk's Net Margin % or its related term are showing as below:
ISX:INAF'
s Net Margin % Range Over the Past 10 Years
Min: -158.99 Med: -2.84 Max: 0.59
Current: -51.46
ISX:INAF's Net Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 5.56
vs ISX:INAF: -51.46
PT Indofarma Tbk (ISX:INAF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
PT Indofarma Tbk Net Margin % Related Terms
PT Indofarma Tbk Net Margin % Historical Data
* Premium members only.
The historical data trend for PT Indofarma Tbk's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:INAF vs ZTS, VTRS, NBIX: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Indofarma Tbk's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Indofarma Tbk Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Indofarma Tbk's Net Margin % distribution charts can be found below:
* The bar in red indicates where PT Indofarma Tbk's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Indofarma Tbk (ISX:INAF) has a Net Margin % of 275.62% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on PT Indofarma Tbk and its competitors.
Is PT Indofarma Tbk's Net Margin % too high?
PT Indofarma Tbk's current Net Margin % is 275.62%. The Drug Manufacturers industry median Net Margin % is 5.56. PT Indofarma Tbk's value of 275.62% is 4857.2% above this industry median. Overall, PT Indofarma Tbk has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does PT Indofarma Tbk's Net Margin % compare to ZTS and VTRS?
PT Indofarma Tbk's Net Margin % of 275.62% can be compared against companies in the Drug Manufacturers industry. The industry median Net Margin % is 5.56. PT Indofarma Tbk's value of 275.62% is 4857.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Indofarma Tbk's current Net Margin % of 275.62% is 4857.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on PT Indofarma Tbk and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Indofarma Tbk's current Net Margin % is 275.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Indofarma Tbk stock overvalued right now?
PT Indofarma Tbk (ISX:INAF) has a current Net Margin % of 275.62%. The stock's GF Value™ is Rp176.99, compared to a current price of Rp126.00 — trading 28.8% below its estimated fair value. The current Net Margin % is 275.62% and 4857.2% above the Drug Manufacturers industry median of 5.56. PT Indofarma Tbk's overall GF Score™ is 8/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For PT Indofarma Tbk (ISX:INAF), the current Net Margin % is 275.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Indofarma Tbk (ISX:INAF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Indofarma Tbk stock appears to be undervalued.
The current stock price of Rp126.00 is trading 28.8% below its estimated GF Value™ of Rp176.99.
Key valuation signals for ISX:INAF:
Net Margin %: 275.62%
GF Value™: Rp176.99 vs. price of Rp126.00 (28.8% below fair value)
Industry Position: 4857.2% above the Drug Manufacturers median
No single metric tells the full story. See the ISX:INAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others. The Medicine business segment includes drug production, marketing distribution, and sales. The Medical Device Segment includes medical devices and other products. Company generates majority revenue from the Medicine segment. The Company classifies its distribution segments based on geographic regions into six areas, namely Java, Sumatra, Kalimantan, Sulawesi, Bali dan West Nusa Tenggara (NTB),as well as the Eastern Indonesia region.
8GF Score
Get the complete analysis for ISX:INAF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:INAF has been successfully added to your 
